Providence Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12M Buy
12,520
+2
+0% +$2.03K 7.61% 1
2025
Q4
$13M Sell
12,518
-128
-1% -$122K 8.13% 1
2025
Q3
$10.4M Sell
12,646
-15
-0.1% -$11.2K 6.54% 3
2025
Q2
$8.09M Sell
12,661
-98
-0.8% -$76.2K 5.55% 3
2025
Q1
$10.2M Buy
12,759
+289
+2% +$240K 7.73% 1
2024
Q4
$9.55M Sell
12,470
-290
-2% -$240K 7.23% 2
2024
Q3
$11.5M Sell
12,760
-26
-0.2% -$23.4K 8.52% 1
2024
Q2
$11.7M Buy
12,786
+10
+0.1% +$8K 9.31% 1
2024
Q1
$9.76M Buy
12,776
+10,393
+436% +$7.4M 8.33% 1
2023
Q4
$1.1M Sell
2,383
-10,548
-82% -$6.16M 0.99% 32
2023
Q3
$6.86M Sell
12,931
-24
-0.2% -$12.4K 7.65% 2
2023
Q2
$6.03M Sell
12,955
-101
-0.8% -$42.4K 6.68% 3
2023
Q1
$4.84M Sell
13,056
-394
-3% -$133K 3.58% 6
2022
Q4
$4.82M Sell
13,450
-141
-1% -$50K 3.58% 7
2022
Q3
$5.02M Sell
13,591
-622
-4% -$197K 3.75% 4
2022
Q2
$4.66M Buy
14,213
+331
+2% +$99.4K 3.36% 7
2022
Q1
$4.06M Buy
13,882
+30
+0.2% +$7.72K 2.61% 11
2021
Q4
$3.57M Sell
13,852
-92
-0.7% -$23.3K 2.25% 12
2021
Q3
$3.21M Sell
13,944
-591
-4% -$146K 2.23% 13
2021
Q2
$3.4M Sell
14,535
-9
-0.1% -$1.81K 2.32% 13
2021
Q1
$2.72M Buy
14,544
+138
+1% +$27K 2% 13
2020
Q4
$2.41M Sell
14,406
-17
-0.1% -$2.54K 2% 13
2020
Q3
$2.13M Sell
14,423
-165
-1% -$25.5K 2.11% 14
2020
Q2
$2.4M Buy
14,588
+101
+0.7% +$15.5K 2.44% 9
2020
Q1
$1.98M Buy
14,487
+23
+0.2% +$3.16K 2.38% 10
2019
Q4
$1.9M Sell
14,464
-1,032
-7% -$120K 1.74% 17
2019
Q3
$1.73M Sell
15,496
-40
-0.3% -$4.45K 1.55% 21
2019
Q2
$1.75M Sell
15,536
-348
-2% -$41K 1.63% 19
2019
Q1
$2.08M Buy
15,884
+196
+1% +$23.8K 1.96% 15
2018
Q4
$1.79M Sell
15,688
-137
-0.9% -$15.3K 1.99% 14
2018
Q3
$1.7M Sell
15,825
-107
-0.7% -$10.7K 1.55% 20
2018
Q2
$1.36M Sell
15,932
-164
-1% -$13.5K 1.32% 27
2018
Q1
$1.22M Buy
+16,096
New +$1.3M 1.8% 21

Other funds holding LLY

Providence Wealth Advisors's LLY Position: Q1 2026 in Review

Providence Wealth Advisors increased its Eli Lilly (LLY) stake by 0.02% in Q1 2026, buying an estimated $2.03K and bringing the position to 12,520 shares worth $12M. The position accounts for 7.61% of the portfolio, ranked #1.

Providence Wealth Advisors first reported a position in LLY in Q1 2018 and has held it in 33 quarters since. The position peaked at $13M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Providence Wealth Advisors held 12,520 shares of Eli Lilly worth $12M as of Q1 2026.
  • Providence Wealth Advisors bought 2 Eli Lilly shares in Q1 2026, an estimated $2.03K.
  • Eli Lilly made up 7.61% of Providence Wealth Advisors's portfolio in Q1 2026, its #1 holding.
  • Providence Wealth Advisors first reported a position in Eli Lilly in Q1 2018 and has held it in 33 quarters since.
  • Providence Wealth Advisors's Eli Lilly position peaked at $13M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Providence Wealth Advisors's 13F filing for Q1 2026, filed 5 May 2026.